Archives of Toxicology

, Volume 84, Issue 12, pp 919–938 | Cite as

Selenium: a double-edged sword for defense and offence in cancer

  • Jela BrozmanováEmail author
  • Dominika Mániková
  • Viera Vlčková
  • Miroslav Chovanec
Review Article


Selenium (Se) is an essential dietary component for animals including humans and is regarded as a protective agent against cancer. Although the mode of anticancer action of Se is not fully understood yet, several mechanisms, such as antioxidant protection by selenoenzymes, specific inhibition of tumor cell growth by Se metabolites, modulation of cell cycle and apoptosis, and effect on DNA repair have all been proposed. Despite the unsupported results of the last SELECT trial, the cancer-preventing activity of Se was demonstrated in majority of the epidemiological studies. Moreover, recent studies suggest that Se has a potential to be used not only in cancer prevention but also in cancer treatment where in combination with other anticancer drugs or radiation, it can increase efficacy of cancer therapy. In combating cancer cells, Se acts as pro-oxidant rather than antioxidant, inducing apoptosis through the generation of oxidative stress. Thus, the inorganic Se compound, sodium selenite (SeL), due to its prooxidant character, represents a promising alternative for cancer therapy. However, this Se compound is highly toxic compared to organic Se forms. Thus, the unregulated intake of dietary or pharmacological Se supplements mainly in the form of SeL has a potential to expose the body tissues to the toxic levels of Se with subsequent negative consequences on DNA integrity. Hence, due to a broad interest to exploit the positive effects of Se on human health and cancer therapy, studies investigating the negative effects such as toxicity and DNA damage induction resulting from high Se intake are also highly required. Here, we review a role of Se in cancer prevention and cancer therapy, as well as mechanisms underlying Se-induced toxicity and DNA injury. Since Saccharomyces cerevisiae has proven a powerful tool for addressing some important questions regarding Se biology, a part of this review is devoted to this model system.


Selenium Cancer Mechanisms of cancer prevention Cancer treatment 



This work was supported by the VEGA Grant Agency of the Slovak Republic (grants no. 2/6082/26 and 1/3243/06).


  1. Al-Taie OH, Uceyler N, Eubner U, Jakob F, Mörk H, Scheurlen M, Brigelius-Flohe R, Schöttker K, Abel J, Thalheimer A, Katzenberger T, Illert B, Melcher R, Köhrle J (2004) Expression profiling and genetic alterations of the selenoproteins GI-GPx and SePP in colorectal carcinogenesis. Nutr Cancer 48:6–14PubMedCrossRefGoogle Scholar
  2. Ames BN, Gold LS (1997) The causes and prevention of cancer: gaining perspective. Environ Health Perspect 105(suppl 4):865–873PubMedCrossRefGoogle Scholar
  3. Ames BN, Shigenaga MK (1992) Oxidants are a major contributor to aging. Ann N Y Acad Sci 663:85–96PubMedCrossRefGoogle Scholar
  4. Anjaria KB, Madhvanath U (1988) Genotoxicity of selenite in diploid yeast. Mutat Res 204:605–614PubMedCrossRefGoogle Scholar
  5. Asfour IA, El-Tehewi MM, Ahmed MH, Abdel-Sattar MA, Moustafa NN, Hegab HM, Fathey OM (2008) High-dose sodium selenite can induce apoptosis of lymphoma cells in adult patients with non-Hodgkin’s lymphoma. Biol Trace Elem Res 127:200–210PubMedCrossRefGoogle Scholar
  6. Avram D, Bakalinsky AT (1997) SSU1 encodes a plasma membrane protein with a central role in a network of proteins conferring sulfite tolerance in Saccharomyces cerevisiae. J Bacteriol 179:5971–5974PubMedGoogle Scholar
  7. Bhattacharyya RS, Husbeck B, Feldman D, Knox SJ (2008) Selenite treatment inhibits LAPC-4 tumor growth and prostate-specific antigen secretion in a xenograft model of human prostate cancer. Int J Radiat Oncol Biol Phys 72:935–940PubMedGoogle Scholar
  8. Biswas S, Talukder G, Sharma A (2000) Chromosome damage induced by selenium salts in human peripheral lymphocytes. Toxicol In Vitro 14:405–408PubMedCrossRefGoogle Scholar
  9. Boiteux S, Gellon L, Guibourt N (2002) Repair of 8-oxoguanine in Saccharomyces cerevisiae: interplay of DNA repair and replication mechanisms. Free Radic Biol Med 32:1244–1253PubMedCrossRefGoogle Scholar
  10. Brozmanová J, Dudáš A, Henriques JA (2001) Repair of oxidative DNA damage-an important factor reducing cancer risk. Minireview. Neoplasma 48:85–93PubMedGoogle Scholar
  11. Calvo A, Xiao N, Kang J, Best CJ, Leiva I, Emmert-Buck MR, Jorcyk C, Green JE (2002) Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors. Cancer Res 62:5325–5335PubMedGoogle Scholar
  12. Chan N, Koch CJ, Bristow RG (2009) Tumor hypoxia as a modifier of DNA strand break and cross-link repair. Curr Mol Med 9:401–410PubMedCrossRefGoogle Scholar
  13. Chen T, Wong YS (2008) Selenocystine induces caspase-independent apoptosis in MCF-7 human breast carcinoma cells with involvement of p53 phosphorylation and reactive oxygen species generation. Int J Biochem Cell Biol 41:666–676PubMedCrossRefGoogle Scholar
  14. Clark LC, Marshall JR (2001) Randomized, controlled chemoprevention trials in populations at very high risk for prostate cancer: elevated prostate-specific antigen and high-grade prostatic intraepithelial neoplasia. Urology 57:185–187PubMedCrossRefGoogle Scholar
  15. Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, Krongrad A, Lesher JL Jr, Park HK, Sanders BB Jr, Smith CL, Taylor JR (1996) Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional prevention of cancer study group. JAMA 276:1957–1963PubMedCrossRefGoogle Scholar
  16. Collinson LP, Dawes IW (1995) Isolation, characterization and overexpression of the yeast gene, GLR1, encoding glutathione reductase. Gene 156:123–127PubMedCrossRefGoogle Scholar
  17. Combs GF Jr, Gray WP (1998) Chemopreventive agents: selenium. Pharmacol Ther 79:179–192PubMedCrossRefGoogle Scholar
  18. Combs GF Jr, Clark LC, Turnbull BW (2001) An analysis of cancer prevention by selenium. Biofactors 14:153–159PubMedCrossRefGoogle Scholar
  19. Daley JM, Palmbos PL, Wu D, Wilson TE (2005) Nonhomologous end joining in yeast. Annu Rev Genet 39:431–451PubMedCrossRefGoogle Scholar
  20. Das A, Desai D, Pittman B, Amin S, El-Bayoumy K (2003) Comparison of the chemopreventive efficacies of 1,4-phenylenebis(methylene)selenocyanate and selenium-enriched yeast on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced lung tumorigenesis in A/J mouse. Nutr Cancer 46:179–185PubMedCrossRefGoogle Scholar
  21. Davis CD, Feng Y, Hein DW, Finley JW (1999) The chemical form of selenium influences 3,2′-dimethyl-4-aminobiphenyl-DNA adduct formation in rat colon. J Nutr 129:63–69PubMedGoogle Scholar
  22. Demple B, Harrison L (1994) Repair of oxidative damage to DNA: enzymology and biology. Annu Rev Biochem 63:915–948PubMedCrossRefGoogle Scholar
  23. Dennert G, Horneber M (2006) Selenium for alleviating the side effects of chemotherapy, radiotherapy and surgery in cancer patients. Cochrane Database Syst Rev 3:CD005037Google Scholar
  24. Dilworth GL, Bandurski RS (1977) Activation of selenate by adenosine 5′-triphosphate sulphurylase from Saccharomyces cerevisiae. Biochem J 163:521–529PubMedGoogle Scholar
  25. Diwadkar-Navsariwala V, Diamond AM (2004) The link between selenium and chemoprevention: a case for selenoproteins. J Nutr 134:2899–2902PubMedGoogle Scholar
  26. Diwadkar-Navsariwala V, Prins GS, Swanson SM, Birch LA, Ray VH, Hedayat S, Lantvit DL, Diamond AM (2006) Selenoprotein deficiency accelerates prostate carcinogenesis in a transgenic model. Proc Natl Acad Sci USA 103:8179–8184PubMedCrossRefGoogle Scholar
  27. Dong Y, Ganther HE, Stewart C, Ip C (2002) Identification of molecular targets associated with selenium-induced growth inhibition in human breast cells using cDNA microarrays. Cancer Res 62:708–714PubMedGoogle Scholar
  28. Dong Y, Zhang H, Hawthorn L, Ganther HE, Ip C (2003) Delineation of the molecular basis for selenium-induced growth arrest in human prostate cancer cells by oligonucleotide array. Cancer Res 63:52–59PubMedGoogle Scholar
  29. Dorr W (2006) Effects of selenium on radiation responses of tumor cells and tissue. Strahlenther Onkol 182:693–695PubMedCrossRefGoogle Scholar
  30. Drake EN (2006) Cancer chemoprevention: selenium as a prooxidant, not an antioxidant. Med Hypotheses 67:318–322PubMedCrossRefGoogle Scholar
  31. Dudáš A, Chovanec M (2004) DNA double-strand break repair by homologous recombination. Mutat Res 566:131–167PubMedCrossRefGoogle Scholar
  32. Dudáš A, Marková E, Vlasáková D, Kolman A, Bartošová Z, Brozmanová J, Chovanec M (2003) The Escherichia coli RecA protein complements recombination defective phenotype of the Saccharomyces cerevisiae rad52 mutant cells. Yeast 20:389–396PubMedCrossRefGoogle Scholar
  33. Dudášová Z, Dudáš A, Chovanec M (2004) Non-homologous end-joining factors of Saccharomyces cerevisiae. FEMS Microbiol Rev 28:581–601PubMedCrossRefGoogle Scholar
  34. Duffield-Lillico AJ, Slate EH, Reid ME, Turnbull BW, Wilkins PA, Combs GF Jr, Park HK, Gross EG, Graham GF, Stratton MS, Marshall JR, Clark LC (2003) Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. J Natl Cancer Inst 95:1477–1481PubMedGoogle Scholar
  35. Dziaman T, Huzarski T, Gackowski D, Rozalski R, Siomek A, Szpila A, Guz J, Lubinski J, Wasowicz W, Roszkowski K, Olinski R (2009) Selenium supplementation reduced oxidative DNA damage in adnexectomized BRCA1 mutations carriers. Cancer Epidemiol Biomarkers Prev 18:2923–2928PubMedCrossRefGoogle Scholar
  36. El-Bayoumy K (2001) The protective role of selenium on genetic damage and on cancer. Mutat Res 475:123–139PubMedGoogle Scholar
  37. El-Bayoumy K, Sinha R (2004) Mechanisms of mammary cancer chemoprevention by organoselenium compounds. Mutat Res 551:181–197PubMedGoogle Scholar
  38. El-Bayoumy K, Sinha R (2005) Molecular chemoprevention by selenium: a genomic approach. Mutat Res 591:224–236PubMedGoogle Scholar
  39. El-Bayoumy K, Chae YH, Upadhyaya P, Meschter C, Cohen LA, Reddy BS (1992) Inhibition of 7,12-dimethylbenz(a)anthracene-induced tumors and DNA adduct formation in the mammary glands of female Sprague–Dawley rats by the synthetic organoselenium compound, 1,4-phenylenebis(methylene)selenocyanate. Cancer Res 52:2402–2407PubMedGoogle Scholar
  40. El-Bayoumy K, Upadhyaya P, Chae YH, Sohn OS, Rao CV, Fiala E, Reddy BS (1995) Chemoprevention of cancer by organoselenium compounds. J Cell Biochem Suppl 22:92–100PubMedCrossRefGoogle Scholar
  41. El-Bayoumy K, Upadhyaya P, Chae YH, Sohn OS, Rao CV, Fiala E, Reddy BS (2003) Comparative action of 1,4-phenylenebis(methylene)selenocyanate and its metabolites against 7,12-dimethylbenz[a]anthracene-DNA adduct in the rat and cell proliferation in rat mammary tumor cells. Chem Biol Interact 146:179–190PubMedCrossRefGoogle Scholar
  42. El-Bayoumy K, Sinha R, Pinto JT, Rivlin RS (2006a) Cancer chemoprevention by garlic and garlic-containing sulfur and selenium compounds. J Nutr 136:864S–869SPubMedGoogle Scholar
  43. El-Bayoumy K, Das A, Narayanan B, Narayanan N, Fiala ES, Desai D, Rao CV, Amin S, Sinha R (2006b) Molecular targets of the chemopreventive agent 1,4-phenylenebis (methylene)-selenocyanate in human non-small cell lung cancer. Carcinogenesis 27:1369–1376PubMedCrossRefGoogle Scholar
  44. Evans MD, Dizdaroglu M, Cooke MS (2004) Oxidative DNA damage and disease: induction, repair and significance. Mutat Res 567:1–61PubMedCrossRefGoogle Scholar
  45. Falcone G, Nickerson WJ (1963) Reduction of selenite by intact yeast cells and cell-free preparations. J Bacteriol 85:754–762PubMedGoogle Scholar
  46. Federico A, Iodice P, Federico P, Del Rio A, Mellone MC, Catalano G, Federico P (2001) Effects of selenium and zinc supplementation on nutritional status in patients with cancer of digestive tract. Eur J Clin Nutr 55:293–297PubMedCrossRefGoogle Scholar
  47. Fels IG, Cheldelin VH (1948) Methionine in selenium poisoning. J Biol Chem 176:819–828PubMedGoogle Scholar
  48. Fels IG, Cheldelin VH (1949) Selenate inhibition studies; the role of sulfate in selenate toxicity in yeast. Arch Biochem 22:402–405PubMedGoogle Scholar
  49. Fels IG, Cheldelin VH (1950) Selenate inhibition studies. IV. Biochemical basis of selenate toxicity in yeast. J Biol Chem 185:803–811PubMedGoogle Scholar
  50. Fischer JL, Mihelc EM, Pollok KE, Smith ML (2007) Chemotherapeutic selectivity conferred by selenium: a role for p53-dependent DNA repair. Mol Cancer Ther 6:355–361PubMedCrossRefGoogle Scholar
  51. Friedberg EC (2000) Biological responses to DNA damage: a perspective in the new millennium. Cold Spring Harb Symp Quant Biol 65:593–602PubMedCrossRefGoogle Scholar
  52. Fulda S (2009) Tumor resistance to apoptosis. Int J Cancer 124:511–515PubMedCrossRefGoogle Scholar
  53. Ganther HE (1971) Reduction of the selenotrisulfide derivative of glutathione to a persulfide analog by glutathione reductase. Biochemistry 10:4089–4098PubMedCrossRefGoogle Scholar
  54. Ganther HE (1978) Modification of methylmercury toxicity and metabolism by selenium and vitamin E: possible mechanisms. Environ Health Perspect 25:71–76PubMedCrossRefGoogle Scholar
  55. Ganther HE (1999) Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase. Carcinogenesis 20:1657–1666PubMedCrossRefGoogle Scholar
  56. Gasch AP, Spellman PT, Kao CM, Carmel-Harel O, Eisen MB, Storz G, Botstein D, Brown PO (2000) Genomic expression programs in the response of yeast cells to environmental changes. Mol Biol Cell 11:4241–4257PubMedGoogle Scholar
  57. Gharieb MM, Gadd GM (1998) Evidence for the involvement of vacuolar activity in metal(loid) tolerance: vacuolar-lacking and -defective mutants of Saccharomyces cerevisiae display higher sensitivity to chromate, tellurite and selenite. Biometals 11:101–106PubMedCrossRefGoogle Scholar
  58. Ghosh J (2004) Rapid induction of apoptosis in prostate cancer cells by selenium: reversal by metabolites of arachidonate 5-lipoxygenase. Biochem Biophys Res Commun 315:624–635PubMedCrossRefGoogle Scholar
  59. Girard PM, Boiteux S (1997) Repair of oxidized DNA bases in the yeast Saccharomyces cerevisiae. Biochimie 79:559–566PubMedCrossRefGoogle Scholar
  60. Gladyshev VN, Factor VM, Housseau F, Hatfield DL (1998) Contrasting patterns of regulation of the antioxidant selenoproteins, thioredoxin reductase, and glutathione peroxidase, in cancer cells. Biochem Biophys Res Commun 251:488–493PubMedCrossRefGoogle Scholar
  61. Gopalakrishna R, Gundimeda U (2001) Protein kinase C as a molecular target for cancer prevention by selenocompounds. Nutr Cancer 40:55–63PubMedCrossRefGoogle Scholar
  62. Gopalakrishna R, Gundimeda U (2002) Antioxidant regulation of protein kinase C in cancer prevention. J Nutr 132:3819S–3823SPubMedGoogle Scholar
  63. Gopalakrishna R, Chen ZH, Gundimeda U (1997) Selenocompounds induce a redox modulation of protein kinase C in the cell, compartmentally independent from cytosolic glutathione: its role in inhibition of tumor promotion. Arch Biochem Biophys 348:37–48PubMedCrossRefGoogle Scholar
  64. Gopee NV, Johnson VJ, Sharma RP (2004) Sodium selenite-induced apoptosis in murine B-lymphoma cells is associated with inhibition of protein kinase C-delta, nuclear factor kappaB, and inhibitor of apoptosis protein. Toxicol Sci 78:204–214PubMedCrossRefGoogle Scholar
  65. Greenlee H, Gammon MD, Abrahamson PE, Gaudet MM, Terry MB, Hershman DL, Desai M, Teitelbaum SL, Neugut AI, Jacobson JS (2009) Prevalence and predictors of antioxidant supplement use during breast cancer treatment: the Long Island breast cancer study project. Cancer 115:3271–3282PubMedCrossRefGoogle Scholar
  66. Grenon M, Costelloe T, Jimeno S, O’Shaughnessy A, Fitzgerald J, Zgheib O, Degerth L, Lowndes NF (2007) Docking onto chromatin via the Saccharomyces cerevisiae Rad9 tudor domain. Yeast 24:105–119PubMedCrossRefGoogle Scholar
  67. Gundimeda U, Schiffman JE, Chhabra D, Wong J, Wu A, Gopalakrishna R (2008) Locally generated methylseleninic acid induces specific inactivation of protein kinase C isoenzymes: relevance to selenium-induced apoptosis in prostate cancer cells. J Biol Chem 283:24519–34531CrossRefGoogle Scholar
  68. Hail N Jr, Cortes M, Drake EN, Spallholz JE (2008) Cancer chemoprevention: a radical perspective. Free Radic Biol Med 45:97–110PubMedCrossRefGoogle Scholar
  69. Hatfield DL, Gladyshev VN (2002) How selenium has altered our understanding of the genetic code. Mol Cell Biol 22:3565–3576PubMedCrossRefGoogle Scholar
  70. Heidenreich E, Eisler H (2004) Non-homologous end joining dependency of gamma-irradiation-induced adaptive frameshift mutation formation in cell cycle-arrested yeast cells. Mutat Res 556:201–208PubMedGoogle Scholar
  71. Heidenreich E, Novotny R, Kneidinger B, Holzmann V, Wintersberger U (2003) Non-homologous end joining as an important mutagenic process in cell cycle-arrested cells. EMBO J 22:2274–2283PubMedCrossRefGoogle Scholar
  72. Hill KE, Zhou J, McMahan WJ, Motley AK, Burk RF (2004) Neurological dysfunction occurs in mice with targeted deletion of the selenoprotein P gene. J Nutr 134:157–161PubMedGoogle Scholar
  73. Hoeijmakers JH (2001) Genome maintenance mechanisms for preventing cancer. Nature 411:366–374PubMedCrossRefGoogle Scholar
  74. Holmgren A (2006) Selenite in cancer therapy: a commentary on “selenite induces apoptosis in sarcomatoid malignant mesothelioma cells through oxidative stress”. Free Radic Biol Med 41:862–865PubMedCrossRefGoogle Scholar
  75. Hu YJ, Diamond AM (2003) Role of glutathione peroxidase 1 in breast cancer: loss of heterozygosity and allelic differences in the response to selenium. Cancer Res 63:3347–3351PubMedGoogle Scholar
  76. Hu YJ, Korotkov KV, Mehta R, Hatfield DL, Rotimi CN, Luke A, Prewitt TE, Cooper RS, Stock W, Vokes EE, Dolan ME, Gladyshev VN, Diamond AM (2001) Distribution and functional consequences of nucleotide polymorphisms in the 3′-untranslated region of the human Sep15 gene. Cancer Res 61:2307–2310PubMedGoogle Scholar
  77. Hu YJ, Dolan ME, Bae R, Yee H, Roy M, Glickman R, Kiremidjian-Schumacher L, Diamond AM (2004) Allelic loss at the GPx-1 locus in cancer of the head and neck. Biol Trace Elem Res 101:97–106PubMedCrossRefGoogle Scholar
  78. Huang F, Nie C, Yang Y, Yue W, Ren Y, Shang Y, Wang X, Jin H, Xu C, Chen Q (2009) Selenite induces redox-dependent Bax activation and apoptosis in colorectal cancer cells. Free Radic Biol Med 46:1186–1196PubMedCrossRefGoogle Scholar
  79. Hurst R, Fairweather-Tait S (2009) Selenium and vitamin E supplementation for cancer prevention. JAMA 301:1876–1877PubMedCrossRefGoogle Scholar
  80. Husbeck B, Peehl DM, Knox SJ (2005) Redox modulation of human prostate carcinoma cells by selenite increases radiation-induced cell killing. Free Radic Biol Med 38:50–57PubMedCrossRefGoogle Scholar
  81. Husbeck B, Bhattacharyya RS, Feldman D, Knox SJ (2006a) Inhibition of androgen receptor signaling by selenite and methylseleninic acid in prostate cancer cells: two distinct mechanisms of action. Mol Cancer Ther 5:2078–2085PubMedCrossRefGoogle Scholar
  82. Husbeck B, Nonn L, Peehl DM, Knox SJ (2006b) Tumor-selective killing by selenite in patient-matched pairs of normal and malignant prostate cells. Prostate 66:218–225PubMedCrossRefGoogle Scholar
  83. Ichimura Y, Habuchi T, Tsuchiya N, Wang L, Oyama C, Sato K, Nishiyama H, Ogawa O, Kato T (2004) Increased risk of bladder cancer associated with a glutathione peroxidase 1 codon 198 variant. J Urol 172:728–732PubMedCrossRefGoogle Scholar
  84. Ip C (1998) Lessons from basic research in selenium and cancer prevention. J Nutr 128:1845–1854PubMedGoogle Scholar
  85. Ip C, Ganther HE (1990) Activity of methylated forms of selenium in cancer prevention. Cancer Res 50:1206–1211PubMedGoogle Scholar
  86. Ip C, Hayes C, Budnick RM, Ganther HE (1991) Chemical form of selenium, critical metabolites, and cancer prevention. Cancer Res 51:595–600PubMedGoogle Scholar
  87. Ip C, Thompson HJ, Zhu Z, Ganther HE (2000) In vitro and in vivo studies of methylseleninic acid: evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res 60:2882–2886PubMedGoogle Scholar
  88. Irons R, Carlson BA, Hatfield DL, Davis CD (2006) Both selenoproteins and low molecular weight selenocompounds reduce colon cancer risk in mice with genetically impaired selenoprotein expression. J Nutr 136:1311–1317PubMedGoogle Scholar
  89. Jablonska E, Gromadzinska J, Sobala W, Reszka E, Wasowicz W (2008) Lung cancer risk associated with selenium status is modified in smoking individuals by Sep15 polymorphism. Eur J Nutr 47:47–54PubMedCrossRefGoogle Scholar
  90. Jackson MI, Combs GF Jr (2008) Selenium and anticarcinogenesis: underlying mechanisms. Curr Opin Clin Nutr Metab Care 11:718–726PubMedCrossRefGoogle Scholar
  91. Jiang C, Ganther H, Lu J (2000) Monomethyl selenium-specific inhibition of MMP-2 and VEGF expression: implications for angiogenic switch regulation. Mol Carcinog 29:236–250PubMedCrossRefGoogle Scholar
  92. Jiang C, Wang Z, Ganther H, Lu J (2001) Caspases as key executors of methyl selenium-induced apoptosis (anoikis) of DU-145 prostate cancer cells. Cancer Res 61:3062–3070PubMedGoogle Scholar
  93. Jiang C, Wang Z, Ganther H, Lu J (2002) Distinct effects of methylseleninic acid versus selenite on apoptosis, cell cycle, and protein kinase pathways in DU145 human prostate cancer cells. Mol Cancer Ther 1:1059–1066PubMedGoogle Scholar
  94. Jiang C, Hu H, Malewicz B, Wang Z, Lu J (2004) Selenite-induced p53 Ser-15 phosphorylation and caspase-mediated apoptosis in LNCaP human prostate cancer cells. Mol Cancer Ther 3:877–884PubMedGoogle Scholar
  95. Juliger S, Goenaga-Infante H, Lister TA, Fitzgibbon J, Joel SP (2007) Chemosensitization of B-cell lymphomas by methylseleninic acid involves nuclear factor-kappaB inhibition and the rapid generation of other selenium species. Cancer Res 67:10984–10992PubMedCrossRefGoogle Scholar
  96. Kaeck M, Lu J, Strange R, Ip C, Ganther HE, Thompson HJ (1997) Differential induction of growth arrest inducible genes by selenium compounds. Biochem Pharmacol 53:921–926PubMedCrossRefGoogle Scholar
  97. Kim IY, Stadtman TC (1997) Inhibition of NF-kappaB DNA binding and nitric oxide induction in human T cells and lung adenocarcinoma cells by selenite treatment. Proc Natl Acad Sci USA 94:12904–12907PubMedCrossRefGoogle Scholar
  98. Kim T, Jung U, Cho DY, Chung AS (2001) Se-methylselenocysteine induces apoptosis through caspase activation in HL-60 cells. Carcinogenesis 22:559–565PubMedCrossRefGoogle Scholar
  99. Kim EH, Sohn S, Kwon HJ, Kim SU, Kim MJ, Lee SJ, Choi KS (2007) Sodium selenite induces superoxide-mediated mitochondrial damage and subsequent autophagic cell death in malignant glioma cells. Cancer Res 67:6314–6324PubMedCrossRefGoogle Scholar
  100. Kiremidjian-Schumacher L, Roy M, Glickman R, Schneider K, Rothstein S, Cooper J, Hochster H, Kim M, Newman R (2000) Selenium and immunocompetence in patients with head and neck cancer. Biol Trace Elem Res 73:97–111PubMedCrossRefGoogle Scholar
  101. Klein EA, Thompson IM, Lippman SM, Goodman PJ, Albanes D, Taylor PR, Coltman C (2000) SELECT: the selenium and vitamin E cancer prevention trial: rationale and design. Prostate Cancer Prostatic Dis 3:145–151PubMedCrossRefGoogle Scholar
  102. Kong Q, Beel JA, Lillehei KO (2000) A threshold concept for cancer therapy. Med Hypotheses 55:29–35PubMedCrossRefGoogle Scholar
  103. Kowalska E, Narod SA, Huzarski T, Zajaczek S, Huzarska J, Gorski B, Lubinski J (2005) Increased rates of chromosome breakage in BRCA1 carriers are normalized by oral selenium supplementation. Cancer Epidemiol Biomarkers Prev 14:1302–1306PubMedCrossRefGoogle Scholar
  104. Kumaraswamy E, Malykh A, Korotkov KV, Kozyavkin S, Hu Y, Kwon SY, Moustafa ME, Carlson BA, Berry MJ, Lee BJ, Hatfield DL, Diamond AM, Gladyshev VN (2000) Structure-expression relationships of the 15-kDa selenoprotein gene. Possible role of the protein in cancer etiology. J Biol Chem 275:35540–35547PubMedCrossRefGoogle Scholar
  105. Lacraustra M, Navas-Acien A, Stranges S, Ordovas JM, Guallar E (2009) Serum selenium concentrations and diabetes in US adults: national health and nutrition examination survey (NHANES) 2003–2004. Environ Health Perspect 117:1409–1413Google Scholar
  106. Laffon B, Valdiglesias V, Pasaro E, Mendez J (2010) The organic selenium compound selenomethionine modulates bleomycin-induced DNA damage and repair in human leukocytes. Biol Trace Elem Res 133:12–19PubMedCrossRefGoogle Scholar
  107. Leer RJ, Raamsdonk-Duin MM, Molenaar CM, Cohen LH, Mager WH, Planta RJ (1982) The structure of the gene coding for the phosphorylated ribosomal protein S10 in yeast. Nucleic Acids Res 10:5869–5878PubMedCrossRefGoogle Scholar
  108. Lehoczký P, McHugh PJ, Chovanec M (2007) DNA interstrand cross-link repair in Saccharomyces cerevisiae. FEMS Microbiol Rev 31:109–133PubMedCrossRefGoogle Scholar
  109. Letavayová L, Vlčková V, Brozmanová J (2006) Selenium: from cancer prevention to DNA damage. Toxicology 227:1–14PubMedCrossRefGoogle Scholar
  110. Letavayová L, Vlasáková D, Spallholz JE, Brozmanová J, Chovanec M (2008a) Toxicity and mutagenicity of selenium compounds in Saccharomyces cerevisiae. Mutat Res 638:1–10PubMedGoogle Scholar
  111. Letavayová L, Vlasáková D, Vlčková V, Brozmanová J, Chovanec M (2008b) Rad52 has a role in the repair of sodium selenite-induced DNA damage in Saccharomyces cerevisiae. Mutat Res 652:198–203PubMedGoogle Scholar
  112. Li GX, Hu H, Jiang C, Schuster T, Lu J (2007) Differential involvement of reactive oxygen species in apoptosis induced by two classes of selenium compounds in human prostate cancer cells. Int J Cancer 120:2034–2043PubMedCrossRefGoogle Scholar
  113. Lincoln DT, Ali Emadi EM, Tonissen KF, Clarke FM (2003) The thioredoxin-thioredoxin reductase system: over-expression in human cancer. Anticancer Res 23:2425–2433PubMedGoogle Scholar
  114. Lipinski B (2005) Rationale for the treatment of cancer with sodium selenite. Med Hypotheses 64:806–810PubMedCrossRefGoogle Scholar
  115. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD III, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the selenium and vitamin E cancer prevention trial (SELECT). JAMA 301:39–51PubMedCrossRefGoogle Scholar
  116. Lopez-Lazaro M, Willmore E, Elliott SL, Austin CA (2008) Selenite induces topoisomerase I and II-DNA complexes in K562 leukemia cells. Int J Cancer 123:2217–2221PubMedCrossRefGoogle Scholar
  117. Lowe SW, Lin AW (2000) Apoptosis in cancer. Carcinogenesis 21:485–495PubMedCrossRefGoogle Scholar
  118. Lu J (2001) Apoptosis and angiogenesis in cancer prevention by selenium. Adv Exp Med Biol 492:131–145PubMedGoogle Scholar
  119. Lu J, Jiang C (2001) Antiangiogenic activity of selenium in cancer chemoprevention: metabolite-specific effects. Nutr Cancer 40:64–73PubMedCrossRefGoogle Scholar
  120. Lu J, Jiang C (2005) Selenium and cancer chemoprevention: hypotheses integrating the actions of selenoproteins and selenium metabolites in epithelial and non-epithelial target cells. Antioxid Redox Signal 7:1715–1727PubMedCrossRefGoogle Scholar
  121. Lu J, Kaeck M, Jiang C, Wilson AC, Thompson HJ (1994) Selenite induction of DNA strand breaks and apoptosis in mouse leukemic L1210 cells. Biochem Pharmacol 47:1531–1535PubMedCrossRefGoogle Scholar
  122. Lu J, Jiang C, Kaeck M, Ganther H, Vadhanavikit S, Ip C, Thompson H (1995) Dissociation of the genotoxic and growth inhibitory effects of selenium. Biochem Pharmacol 50:213–219PubMedCrossRefGoogle Scholar
  123. Machado MS, Villela IV, Moura DJ, Rosa RM, Salvador M, Lopes NP, Braga AL, Roesler R, Saffi J, Henriques JA (2009) 3′3-Ditrifluoromethyldiphenyl diselenide: a new organoselenium compound with interesting antigenotoxic and antimutagenic activities. Mutat Res 673:133–140Google Scholar
  124. Mahaney BL, Meek K, Lees-Miller SP (2009) Repair of ionizing radiation-induced DNA double-strand breaks by non-homologous end-joining. Biochem J 417:639–650PubMedCrossRefGoogle Scholar
  125. Mániková D, Vlasáková D, Loduhová J, Letavayová L, Vigašová D, Krascsenitsová E, Vlčková V, Brozmanová J, Chovanec M (2010) Investigations on the role of base excision repair and non-homologous end-joining pathways in sodium selenite-induced toxicity and mutagenicity in Saccharomyces cerevisiae. Mutagenesis 25:155–162PubMedCrossRefGoogle Scholar
  126. Manzanares W, Hardy G (2009) Selenium supplementation in the critically ill: posology and pharmacokinetics. Curr Opin Clin Nutr Metab Care 12:273–280PubMedCrossRefGoogle Scholar
  127. Maynard S, Schurman SH, Harboe C, Souza-Pinto NC, Bohr VA (2009) Base excision repair of oxidative DNA damage and association with cancer and aging. Carcinogenesis 30:2–10PubMedCrossRefGoogle Scholar
  128. Memisoglu A, Samson L (2000) Base excision repair in yeast and mammals. Mutat Res 451:39–51PubMedGoogle Scholar
  129. Menter DG, Sabichi AL, Lippman SM (2000) Selenium effects on prostate cell growth. Cancer Epidemiol Biomarkers Prev 9:1171–1182PubMedGoogle Scholar
  130. Meplan C, Nicol F, Burtle BT, Crosley LK, Arthur JR, Mathers JC, Hesketh JE (2009) Relative abundance of selenoprotein P isoforms in human plasma depends on genotype, se intake, and cancer status. Antioxid Redox Signal 11:2631–2640PubMedCrossRefGoogle Scholar
  131. Meuillet E, Stratton S, Prasad CD, Goulet AC, Kagey J, Porterfield B, Nelson MA (2004) Chemoprevention of prostate cancer with selenium: an update on current clinical trials and preclinical findings. J Cell Biochem 91:443–458PubMedCrossRefGoogle Scholar
  132. Micke O, Bruns F, Mucke R, Schafer U, Glatzel M, de Vries AF, Schonekaes K, Kisters K, Buntzel J (2003) Selenium in the treatment of radiation-associated secondary lymphedema. Int J Radiat Oncol Biol Phys 56:40–49PubMedGoogle Scholar
  133. Micke O, Schomburg L, Buentzel J, Kisters K, Muecke R (2009) Selenium in oncology: from chemistry to clinics. Molecules 14:3975–3988PubMedCrossRefGoogle Scholar
  134. Moghadaszadeh B, Beggs AH (2006) Selenoproteins and their impact on human health through diverse physiological pathways. Physiology (Bethesda) 21:307–315Google Scholar
  135. Moos PJ, Edes K, Cassidy P, Massuda E, Fitzpatrick FA (2003) Electrophilic prostaglandins and lipid aldehydes repress redox-sensitive transcription factors p53 and hypoxia-inducible factor by impairing the selenoprotein thioredoxin reductase. J Biol Chem 278:745–750PubMedCrossRefGoogle Scholar
  136. Mork H, Al Taie OH, Bahr K, Zierer A, Beck C, Scheurlen M, Jakob F, Kohrle J (2000) Inverse mRNA expression of the selenocysteine-containing proteins GI-GPx and SeP in colorectal adenomas compared with adjacent normal mucosa. Nutr Cancer 37:108–116PubMedCrossRefGoogle Scholar
  137. Moscow JA, Schmidt L, Ingram DT, Gnarra J, Johnson B, Cowan KH (1994) Loss of heterozygosity of the human cytosolic glutathione peroxidase I gene in lung cancer. Carcinogenesis 15:2769–2773PubMedCrossRefGoogle Scholar
  138. Mustacich D, Powis G (2000) Thioredoxin reductase. Biochem J 346(Pt 1):1–8PubMedCrossRefGoogle Scholar
  139. Narayanan BA (2006) Chemopreventive agents alters global gene expression pattern: predicting their mode of action and targets. Curr Cancer Drug Targets 6:711–727PubMedCrossRefGoogle Scholar
  140. Nasr MA, Fedele MJ, Esser K, Diamond AM (2004) GPx-1 modulates Akt and P70S6K phosphorylation and Gadd45 levels in MCF-7 cells. Free Radic Biol Med 37:187–195PubMedCrossRefGoogle Scholar
  141. Nilsonne G, Sun X, Nyström C, Rundlöf AK, Potamitou FA, Björnstedt M, Dobra K (2006) Selenite induces apoptosis in sarcomatoid malignant mesothelioma cells through oxidative stress. Free Radic Biol Med 41:874–885PubMedCrossRefGoogle Scholar
  142. Novotný L, Rauko P, Kombian SB, Edafiogho IO (2010) Selenium as chemoprotective anti-cancer agent: reality or wishful thinking? Neoplasma 57:383–391PubMedCrossRefGoogle Scholar
  143. Olm E, Fernandes AP, Hebert C, Rundlöf AK, Larsen EH, Danielsson O, Björnstedt M (2009a) Extracellular thiol-assisted selenium uptake dependent on the x(c)-cystine transporter explains the cancer-specific cytotoxicity of selenite. Proc Natl Acad Sci USA 106:11400–11405PubMedCrossRefGoogle Scholar
  144. Olm E, Jonsson-Videsater K, Ribera-Cortada I, Fernandes AP, Eriksson LC, Lehmann S, Rundlöf AK, Paul C, Björnstedt M (2009b) Selenite is a potent cytotoxic agent for human primary AML cells. Cancer Lett 282:116–123PubMedCrossRefGoogle Scholar
  145. Painter EP (1941) The chemistry and toxicity of selenium compounds with special reference to the selenium problem. Chem Rev 28:179–213CrossRefGoogle Scholar
  146. Pan JS, Hong MZ, Ren JL (2009) Reactive oxygen species: a double-edged sword in oncogenesis. World J Gastroenterol 15:1702–1707PubMedCrossRefGoogle Scholar
  147. Papp LV, Lu J, Holmgren A, Khanna KK (2007) From selenium to selenoproteins: synthesis, identity, and their role in human health. Antioxid Redox Signal 9:775–806PubMedCrossRefGoogle Scholar
  148. Pearson GD, Merrill GF (1998) Deletion of the Saccharomyces cerevisiae TRR1 gene encoding thioredoxin reductase inhibits p53-dependent reporter gene expression. J Biol Chem 273:5431–5434PubMedCrossRefGoogle Scholar
  149. Persson-Moschos ME, Stavenow L, Akesson B, Lindgärde F (2000) Selenoprotein P in plasma in relation to cancer morbidity in middle-aged Swedish men. Nutr Cancer 36:19–26PubMedCrossRefGoogle Scholar
  150. Petronilli V, Nicolli A, Costantini P, Colonna R, Bernardi P (1994) Regulation of the permeability transition pore, a voltage-dependent mitochondrial channel inhibited by cyclosporin A. Biochim Biophys Acta 1187:255–259PubMedCrossRefGoogle Scholar
  151. Pinson B, Sagot I, Daignan-Fornier B (2000) Identification of genes affecting selenite toxicity and resistance in Saccharomyces cerevisiae. Mol Microbiol 36:679–687PubMedCrossRefGoogle Scholar
  152. Platz EA, Lippman SM (2009) Selenium, genetic variation, and prostate cancer risk: epidemiology reflects back on selenium and vitamin E cancer prevention trial. J Clin Oncol 27:3569–3572PubMedCrossRefGoogle Scholar
  153. Prokopczyk B, Cox JE, Upadhyaya P, Amin S, Desai D, Hoffmann D, El-Bayoumy K (1996) Effects of dietary 1,4-phenylenebis(methylene)selenocyanate on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced DNA adduct formation in lung and liver of A/J mice and F344 rats. Carcinogenesis 17:749–753PubMedCrossRefGoogle Scholar
  154. Rafferty TS, Green MH, Lowe JE, Arlett C, Hunter JA, Beckett GJ, McKenzie RC (2003) Effects of selenium compounds on induction of DNA damage by broadband ultraviolet radiation in human keratinocytes. Br J Dermatol 148:1001–1009PubMedCrossRefGoogle Scholar
  155. Ratnasinghe D, Tangrea JA, Andersen MR, Barrett MJ, Virtamo J, Taylor PR, Albanes D (2000) Glutathione peroxidase codon 198 polymorphism variant increases lung cancer risk. Cancer Res 60:6381–6383PubMedGoogle Scholar
  156. Rayman MP (2005) Selenium in cancer prevention: a review of the evidence and mechanism of action. Proc Nutr Soc 64:527–542PubMedCrossRefGoogle Scholar
  157. Rayman MP (2008) Food-chain selenium and human health: emphasis on intake. Br J Nutr 100:238–253PubMedGoogle Scholar
  158. Rayman MP (2009) Selenoproteins and human health: insights from epidemiological data. Biochim Biophys Acta 1790:1533–1540PubMedGoogle Scholar
  159. Rayman MP, Combs GF Jr, Waters DJ (2009) Selenium and vitamin E supplementation for cancer prevention. JAMA 301:1876PubMedCrossRefGoogle Scholar
  160. RC IA (1987) Overall evaluations of carcinogenicity: an updating of IARC Monographs volumes 1–42. IARC Monogr Eval Carcinog Risks Hum Suppl 7:1–440Google Scholar
  161. Reeves PG, Leary PD, Gregoire BR, Finley JW, Lindlauf JE, Johnson LK (2005) Selenium bioavailability from buckwheat bran in rats fed a modified AIN-93G torula yeast-based diet. J Nutr 135:2627–2633PubMedGoogle Scholar
  162. Reid ME, Stratton MS, Lillico AJ, Fakih M, Natarajan R, Clark LC, Marshall JR (2004) A report of high-dose selenium supplementation: response and toxicities. J Trace Elem Med Biol 18:69–74PubMedCrossRefGoogle Scholar
  163. Richie JP Jr, Kleinman W, Desai DH, Das A, Amin SG, Pinto JT, El-Bayoumy K (2006) The organoselenium compound 1,4-phenylenebis(methylene)selenocyanate inhibits 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced tumorgenesis and enhances glutathione-related antioxidant levels in A/J mouse lung. Chem Biol Interact 161:93–103PubMedCrossRefGoogle Scholar
  164. Rudolf E, Radocha J, Cervinka M, Cerman J (2004) Combined effect of sodium selenite and campthotecin on cervical carcinoma cells. Neoplasma 51:127–135PubMedGoogle Scholar
  165. Salin H, Fardeau V, Piccini E, Lelandais G, Tanty V, Lemoine S, Jacq C, Devaux F (2008) Structure and properties of transcriptional networks driving selenite stress response in yeasts. BMC Genomics 9:333PubMedCrossRefGoogle Scholar
  166. Sanmartin C, Plano D, Palop JA (2008) Selenium compounds and apoptotic modulation: a new perspective in cancer therapy. Mini Rev Med Chem 8:1020–1031PubMedCrossRefGoogle Scholar
  167. Schrauzer GN (2000) Selenomethionine: a review of its nutritional significance, metabolism and toxicity. J Nutr 130:1653–1656PubMedGoogle Scholar
  168. Schrauzer GN (2001) Nutritional selenium supplements: product types, quality, and safety. J Am Coll Nutr 20:1–4PubMedGoogle Scholar
  169. Schueller P, Puettmann S, Micke O, Senner V, Schaefer U, Willich N (2004) Selenium influences the radiation sensitivity of C6 rat glioma cells. Anticancer Res 24:2913–2917PubMedGoogle Scholar
  170. Schumacker PT (2006) Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell 10:175–176PubMedCrossRefGoogle Scholar
  171. Schwarz K, Foltz CM (1957) Selenium as integral part of factor 3 against dietary liver degeneration. J Am Chem Soc 79:3292–3293CrossRefGoogle Scholar
  172. Schwarz K, Foltz CM (1958) Factor 3 activity of selenium compounds. J Biol Chem 233:245–251PubMedGoogle Scholar
  173. Seitomer E, Balar B, He D, Copeland PR, Kinzy TG (2008) Analysis of Saccharomyces cerevisiae null allele strains identifies a larger role for DNA damage versus oxidative stress pathways in growth inhibition by selenium. Mol Nutr Food Res 52:1305–1315PubMedCrossRefGoogle Scholar
  174. Seko Y, Saito Y, Kitahara J, Imura N (1989) Active oxygen generation by the reaction of selenite with reduced glutathione in vitro. In: Wendel A (ed) Selenium in biology and medicine. Springer, Berlin, pp 70–73Google Scholar
  175. Selenius M, Fernandes AP, Brodin O, Björnstedt M, Rundlöf AK (2008) Treatment of lung cancer cells with cytotoxic levels of sodium selenite: effects on the thioredoxin system. Biochem Pharmacol 75:2092–2099PubMedCrossRefGoogle Scholar
  176. Selenius M, Rundlof AK, Olm E, Fernandes AP, Björnstedt M (2010) Selenium and selenoproteins in the treatment and diagnostics of cancer. Antioxid Redox Signal 12:867–880PubMedCrossRefGoogle Scholar
  177. Seo YR, Sweeney C, Smith ML (2002a) Selenomethionine induction of DNA repair response in human fibroblasts. Oncogene 21:3663–3669PubMedCrossRefGoogle Scholar
  178. Seo YR, Kelley MR, Smith ML (2002b) Selenomethionine regulation of p53 by a ref1-dependent redox mechanism. Proc Natl Acad Sci USA 99:14548–14553PubMedCrossRefGoogle Scholar
  179. Shamberger RJ, Frost DV (1969) Possible protective effect of selenium against human cancer. Can Med Assoc J 100:682PubMedGoogle Scholar
  180. Shin SH, Yoon MJ, Kim M, Kim JI, Lee SJ, Lee YS, Bae S (2007) Enhanced lung cancer cell killing by the combination of selenium and ionizing radiation. Oncol Rep 17:209–216PubMedGoogle Scholar
  181. Shiobara Y, Yoshida T, Suzuki KT (1998) Effects of dietary selenium species on Se concentrations in hair, blood, and urine. Toxicol Appl Pharmacol 152:309–314PubMedCrossRefGoogle Scholar
  182. Sieja K, Talerczyk M (2004) Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy. Gynecol Oncol 93:320–327PubMedCrossRefGoogle Scholar
  183. Sinha R, El-Bayoumy K (2004) Apoptosis is a critical cellular event in cancer chemoprevention and chemotherapy by selenium compounds. Curr Cancer Drug Targets 4:13–28PubMedCrossRefGoogle Scholar
  184. Sinha R, Said TK, Medina D (1996) Organic and inorganic selenium compounds inhibit mouse mammary cell growth in vitro by different cellular pathways. Cancer Lett 107:277–284PubMedCrossRefGoogle Scholar
  185. Sinha R, Kiley SC, Lu JX, Thompson HJ, Moraes R, Jaken S, Medina D (1999) Effects of methylselenocysteine on PKC activity, cdk2 phosphorylation and gadd gene expression in synchronized mouse mammary epithelial tumor cells. Cancer Lett 146:135–145PubMedCrossRefGoogle Scholar
  186. Sohn OS, Fiala ES, Upadhyaya P, Chae YH, El-Bayoumy K (1999) Comparative effects of phenylenebis(methylene)selenocyanate isomers on xenobiotic metabolizing enzymes in organs of female CD rats. Carcinogenesis 20:615–621PubMedCrossRefGoogle Scholar
  187. Spallholz JE (1997) Free radical generation by selenium compounds and their prooxidant toxicity. Biomed Environ Sci 10:260–270PubMedGoogle Scholar
  188. Spallholz JE, Palace VP, Reid TW (2004) Methioninase and selenomethionine but not Se-methylselenocysteine generate methylselenol and superoxide in an in vitro chemiluminescent assay: implications for the nutritional carcinostatic activity of selenoamino acids. Biochem Pharmacol 67:547–554PubMedCrossRefGoogle Scholar
  189. Spyrou G, Björnstedt M, Kumar S, Holmgren A (1995) AP-1 DNA-binding activity is inhibited by selenite and selenodiglutathione. FEBS Lett 368:59–63PubMedCrossRefGoogle Scholar
  190. Squires J, Berry MJ (2006) Selenium, selenoproteins, and cancer. Hawaii Med J 65:239–240PubMedGoogle Scholar
  191. Stadtman TC (2002) Discoveries of vitamin B12 and selenium enzymes. Annu Rev Biochem 71:1–16PubMedCrossRefGoogle Scholar
  192. Stewart MS, Spallholz JE, Neldner KH, Pence BC (1999) Selenium compounds have disparate abilities to impose oxidative stress and induce apoptosis. Free Radic Biol Med 26:42–48PubMedCrossRefGoogle Scholar
  193. Stranges S, Marshall JR, Natarajan R, Donahue RP, Trevisan M, Combs GF, Cappuccio FP, Ceriello A, Reid ME (2007) Effects of long-term selenium supplementation on the incidence of Type 2 diabetes. Ann Intern Med 147:217–224PubMedGoogle Scholar
  194. Sutter ME, Thomas JD, Brown J, Morgan B (2008) Selenium toxicity: a case of selenosis caused by a nutritional supplement. Ann Intern Med 148:970–971PubMedGoogle Scholar
  195. Suzuki KT, Kurasaki K, Suzuki N (2007) Selenocysteine beta-lyase and methylselenol demethylase in the metabolism of Se-methylated selenocompounds into selenide. Biochim Biophys Acta 1770:1053–1061PubMedGoogle Scholar
  196. Suzuki M, Endo M, Shinohara F, Echigo S, Rikiishi H (2010) Differential apoptotic response of human cancer cells to organoselenium compounds. Cancer Chemother Pharmacol 66:475–484PubMedCrossRefGoogle Scholar
  197. Szatrowski TP, Nathan CF (1991) Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 51:794–798PubMedGoogle Scholar
  198. Tabassum A, Bristow RG, Venkateswaran V (2010) Ingestion of selenium and other antioxidants during prostate cancer radiotherapy: a good thing? Cancer Treat Rev 36:230–234PubMedCrossRefGoogle Scholar
  199. Tarze A, Dauplais M, Grigoras I, Lazard M, Ha-Duong NT, Barbier F, Blanquet S, Plateau P (2007) Extracellular production of hydrogen selenide accounts for thiol-assisted toxicity of selenite against Saccharomyces cerevisiae. J Biol Chem 282:8759–8767PubMedCrossRefGoogle Scholar
  200. Thant AA, Wu Y, Lee J, Mishra DK, Garcia H, Koeffler HP, Vadgama JV (2008) Role of caspases in 5-FU and selenium-induced growth inhibition of colorectal cancer cells. Anticancer Res 28:3579–3592PubMedGoogle Scholar
  201. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, Chiao PJ, Achanta G, Arlinghaus RB, Liu J, Huang P (2006) Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 10:241–252PubMedCrossRefGoogle Scholar
  202. Trachootham D, Lu W, Ogasawara MA, Nilsa RD, Huang P (2008) Redox regulation of cell survival. Antioxid Redox Signal 10:1343–1374PubMedCrossRefGoogle Scholar
  203. Trachootham D, Alexandre J, Huang P (2009) Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 8:579–591PubMedCrossRefGoogle Scholar
  204. Vadgama JV, Wu Y, Shen D, Hsia S, Block J (2000) Effect of selenium in combination with Adriamycin or Taxol on several different cancer cells. Anticancer Res 20:1391–1414PubMedGoogle Scholar
  205. Valdiglesias V, Pasaro E, Mendez J, Laffon B (2010) In vitro evaluation of selenium genotoxic, cytotoxic, and protective effects: a review. Arch Toxicol 84:337–351PubMedCrossRefGoogle Scholar
  206. Valentine WM, Hill KE, Austin LM, Valentine HL, Goldowitz D, Burk RF (2005) Brainstem axonal degeneration in mice with deletion of selenoprotein P. Toxicol Pathol 33:570–576PubMedCrossRefGoogle Scholar
  207. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J (2007) Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39:44–84PubMedCrossRefGoogle Scholar
  208. van der Kemp PA, Thomas D, Barbey R, Deoliveira R, Boiteux S (1996) Cloning and expression in Escherichia coli of the OGG1 gene of Saccharomyces cerevisiae, which codes for a DNA glycosylase that excises 7,8-dihydro-8-oxoguanine and 2,6-diamino-4-hydroxy-5-N-methylformamidopyrimidine. Proc Natl Acad Sci USA 93:5197–5202PubMedCrossRefGoogle Scholar
  209. Vincent JL, Forceville X (2008) Critically elucidating the role of selenium. Curr Opin Anaesthesiol 21:148–154PubMedCrossRefGoogle Scholar
  210. Wang Z, Jiang C, Lu J (2002) Induction of caspase-mediated apoptosis and cell-cycle G1 arrest by selenium metabolite methylselenol. Mol Carcinog 34:113–120PubMedCrossRefGoogle Scholar
  211. Weterings E, Chen DJ (2008) The endless tale of non-homologous end-joining. Cell Res 18:114–124PubMedCrossRefGoogle Scholar
  212. Whanger PD (2004) Selenium and its relationship to cancer: an update dagger. Br J Nutr 91:11–28PubMedCrossRefGoogle Scholar
  213. Wilson LG, Bandurski RS (1958) Enzymatic reactions involving sulfate, sulfite, selenate, and molybdate. J Biol Chem 233:975–981PubMedGoogle Scholar
  214. Wycherly BJ, Moak MA, Christensen MJ (2004) High dietary intake of sodium selenite induces oxidative DNA damage in rat liver. Nutr Cancer 48:78–83PubMedCrossRefGoogle Scholar
  215. Xiang N, Zhao R, Zhong W (2009) Sodium selenite induces apoptosis by generation of superoxide via the mitochondrial-dependent pathway in human prostate cancer cells. Cancer Chemother Pharmacol 63:351–362PubMedCrossRefGoogle Scholar
  216. Yan L, Spallholz JE (1993) Generation of reactive oxygen species from the reaction of selenium compounds with thiols and mammary tumor cells. Biochem Pharmacol 45:429–437PubMedGoogle Scholar
  217. Yang GQ, Wang SZ, Zhou RH, Sun SZ (1983) Endemic selenium intoxication of humans in China. Am J Clin Nutr 37:872–881PubMedGoogle Scholar
  218. Yang G, Yin S, Zhou R, Gu L, Yan B, Liu Y, Liu Y (1989) Studies of safe maximal daily dietary Se-intake in a seleniferous area in China. Part II: Relation between Se-intake and the manifestation of clinical signs and certain biochemical alterations in blood and urine. J Trace Elem Electrolytes Health Dis 3:123–130PubMedGoogle Scholar
  219. Yoo MH, Xu XM, Carlson BA, Gladyshev VN, Hatfield DL (2006) Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. J Biol Chem 281:13005–13008PubMedCrossRefGoogle Scholar
  220. Zeng H (2009) Selenium as an essential micronutrient: roles in cell cycle and apoptosis. Molecules 14:1263–1278PubMedCrossRefGoogle Scholar
  221. Zeng H, Combs GF Jr (2008) Selenium as an anticancer nutrient: roles in cell proliferation and tumor cell invasion. J Nutr Biochem 19:1–7PubMedCrossRefGoogle Scholar
  222. Zeng H, Wu M, Botnen JH (2009) Methylselenol, a selenium metabolite, induces cell cycle arrest in G1 phase and apoptosis via the extracellular-regulated kinase 1/2 pathway and other cancer signaling genes. J Nutr 139:1613–1618PubMedCrossRefGoogle Scholar
  223. Zhong W, Oberley TD (2001) Redox-mediated effects of selenium on apoptosis and cell cycle in the LNCaP human prostate cancer cell line. Cancer Res 61:7071–7078PubMedGoogle Scholar
  224. Zhou N, Xiao H, Li TK, Nur-E-Kamal A, Liu LF (2003) DNA damage-mediated apoptosis induced by selenium compounds. J Biol Chem 278:29532–29537PubMedCrossRefGoogle Scholar
  225. Zhu Z, Jiang W, Ganther HE, Thompson HJ (2002) Mechanisms of cell cycle arrest by methylseleninic acid. Cancer Res 62:156–164PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Jela Brozmanová
    • 1
    Email author
  • Dominika Mániková
    • 1
  • Viera Vlčková
    • 2
  • Miroslav Chovanec
    • 1
  1. 1.Laboratory of Molecular GeneticsCancer Research InstituteBratislavaSlovak Republic
  2. 2.Department of Genetics, Faculty of Natural SciencesComenius UniversityBratislavaSlovak Republic

Personalised recommendations